A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

American Heart Journal

Volumn 150, Issue 3, 2005, Pages 401.e1-401.e7

  Bhatt, Deepak L ^a   Fox, Keith A ^a   Hacke, Werner ^a   Berger, Peter B ^a   Black, Henry R ^a   Boden, William E ^a   Cacoub, Patrice ^a   Cohen, Eric A ^a   Creager, Mark A ^a   Easton, J Donald ^a   Flather, Marcus D ^a   Haffner, Steven M ^a   Hamm, Christian W ^a   Hankey, Graeme J ^a   Johnston, S Claiborne ^a   Mak, Koon Hou ^a   Mas, Jean Louis ^a   Montalescot, Gilles ^a   Pearson, Thomas A ^a   Steg, P Gabriel ^a   Steinhubl, Steven R ^a   Weber, Michael A ^a   Booth, Joan ^a   Topol, Eric J ^a   more..

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ADENOSINE RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEVINOLIN; NICOTINIC ACID; NITRATE; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; TICLOPIDINE;

ADULT; AGED; ARTERY DISEASE; ARTICLE; ATHEROMA; ATHEROTHROMBOSIS; BODY MASS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; OBESITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOSIS; VASCULAR DISEASE;

EID: 24944483166     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.03.017     Document Type: Article

References (21)

1. P.A. Ringleb, D.L. Bhatt, and A.T. Hirsch Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events Stroke 35 2004 528 532
2. S.M. Haffner, S. Lehto, and T. Ronnemaa Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
3. Antithrombic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
4. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
5. S.R. Steinhubl, P.B. Berger, and J.T. Mann III Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420
6. S. Yusuf, F. Zhao, and S.R. Mehta Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
7. S.R. Mehta, S. Yusuf, and R.J. Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
8. D.L. Bhatt, and E.J. Topol Scientific and therapeutic advances in antiplatelet therapy Nat Rev Drug Discov 2 2003 15 28
9. D.L. Bhatt, and E.J. Topol Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial Am Heart J 148 2004 263 268
10. K.M. Narayan, J.P. Boyle, and T.J. Thompson Lifetime risk for diabetes mellitus in the United States JAMA 290 2003 1884 1890
11. E. Duncan Filling the world's belly Economist 369 2003 3 7
12. S.C. Black Cannabinoid receptor antagonists and obesity Curr Opin Investig Drugs 5 2004 389 394
13. M. Sacco, F. Pellegrini, and M.C. Roncaglioni Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial Diabetes Care 26 2003 3264 3272
14. D. Bhatt, S. Marso, and A. Hirsch Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus Am J Cardiol 90 2002 625 628
15. A. Hartmann, T. Rundek, and H. Mast Mortality and causes of death after first ischemic stroke: the Northern Manhattan Stroke Study Neurology 57 2001 2000 2005
16. M.H. Criqui Peripheral arterial disease-epidemiological aspects Vasc Med 6 3 Suppl. 2001 3 7
17. D.L. Bhatt Peripheral arterial disease in the catheterization laboratory: an underdetected and undertreated risk factor Mayo Clin Proc 79 2004 1107 1109
18. E.J. Topol, D. Easton, and R.A. Harrington Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease Circulation 108 2003 399 406
19. R.J. Peters, S.R. Mehta, and K.A. Fox Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study Circulation 108 2003 1682 1687
20. U.S. Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: recommendation and rationale Ann Intern Med 136 2002 157 160
21. P.S. Sanmuganathan, P. Ghahramani, and P.R. Jackson Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials Heart 85 2001 265 271